D-0298-2021 Class III Terminated

Recalled by Jubilant Cadista Pharmaceuticals, Inc. — Salisbury, MD

FDA drug recall D-0298-2021 was initiated by Jubilant Cadista Pharmaceuticals, Inc. on Feb 19, 2021 and is designated Class III. Reason for recall: Labeling: Illegible label: Customer complaint received of mis-alignment print of the printed dosing instructions on the blister card. The recall status is terminated (terminated Nov 15, 2022). Affected quantity: 635,400 cartons.

Recall details

Product Type
Drugs
Report Date
Mar 10, 2021
Initiation Date
Feb 19, 2021
Termination Date
Nov 15, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
635,400 cartons

Product description

Methylprednisolone Tablets USP, 4 MG, packaged in a 21-count blister pack, Rx only, Jubilant Cadista Pharmaceuticals, Inc., Salisbury, MD 21801, NDC 59746-001-03

Reason for recall

Labeling: Illegible label: Customer complaint received of mis-alignment print of the printed dosing instructions on the blister card.

Distribution pattern

USA nationwide, including Puerto Rico.

Code information

Lot #: 20K0043P, 20K0044P, 20K0042P, Exp 08/2022; 20L0026P, 20L0027P, 20L0028P, 20L0029P, 20L0030P, Exp 09/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0298-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0298-2021. Report a data issue: hello@regdatalab.com.